Date: 2018-01-04
Type of information: Nomination
Compound: vice-president
Company: Adaptimmune (UK)
Therapeutic area: Cancer - Oncology
Type agreement: nomination
Action mechanism:
Disease:
Details:
- • On January 4, 2018, Adaptimmune Therapeutics announced that Paul Stead has joined the company as vice president of business development. Paul joins Adaptimmune, most recently, from Inovio Pharmaceuticals,developing DNA-based immunotherapies within oncology and infectious diseases. Prior to that, he was with Nimbus Therapeutics where he played a key role in Gilead’s acquisition of Nimbus’s comprised Acetyl CoA carboxylase inhibitors program for treatment of NASH and related disorders.
- Paul is a scientist by background earning a BSc, then PhD in Pharmaceutical Sciences from Bath and Nottingham Universities in the UK, respectively, after which he joined GSK as a Senior Scientist in Chemistry BioProcess Development. He progressed from R&D in GSK’s Natural Product Chemistry Department to lead Competitive and Scientific Intelligence in the US. Subsequently, Paul worked up through technology licensing, and senior business development roles in GSK Worldwide Business Development Transactions and then specifically Platform Technology and Science Business Development.
Financial terms:
Latest news:
Is general: Yes
